DNA Methylation Profiling Identifies Distinct Clinical and Pathological Subtypes of Pituitary Neuroendocrine Tumors

Research from New York University (NYU) Langone Health has presented fresh data on pituitary neuroendocrine tumors (PitNETs), highlighting their classification challenges and the benefits of using DNA methylation for clinicopathological stratification. The study analyzed clinical, immunohistochemical, and DNA methylation data of 118 PitNETs and developed a clinicomolecular approach to classify PitNETs and identify epigenetic classes. The researchers found that CNS DNA methylation classifier has an excellent performance in recognizing PitNETs and distinguishing the 3 lineages.

Key Takeaways:

• PitNETs are the most common intracranial neuroendocrine tumors and can be challenging to classify, with current recommendations including a large immunohistochemical panel to differentiate among 14 WHO-recognized categories.
• The study used a clinicomolecular approach to classify PitNETs and identify epigenetic classes, analyzing clinical, immunohistochemical, and DNA methylation data of 118 PitNETs.
• The CNS DNA methylation classifier had an excellent performance in recognizing PitNETs and distinguishing the 3 lineages when the calibrated score is = 0.3.
• The research identified two major clusters of PitNETs: silent gonadotrophs and corticotrophs and Pit1 lineage PitNETs.
• Analysis of promoter methylation patterns correlated with lineage for corticotrophs and Pit1 lineage subtypes, but the gonadotrophic genes did not show a distinct promoter methylation pattern in gonadotroph tumors.
• The research concluded that classification of PitNETs may benefit from DNA methylation for clinicopathological stratification.

Statistics:

• 118 PitNETs were analyzed in the study.
• 14 WHO-recognized categories were classified using a large immunohistochemical panel.
• 2 major clusters of PitNETs were identified: silent gonadotrophs and corticotrophs and Pit1 lineage PitNETs.
• The CNS DNA methylation classifier had an excellent performance in recognizing PitNETs with a calibrated score of = 0.3.

Sources:

• Dna Methylation Profiling of Pituitary Neuroendocrine Tumors Identifies Distinct Clinical and Pathological Subtypes Based On Epigenetic Differentiation. Neuro-Oncology, 2025.
• Oxford Univ Press Inc, Journals Dept, 2001 Evans Rd, Cary, NC 27513, USA.
• Matija Snuderl, New York University (NYU) Langone Health, Nyu Grossman Sch Med, Dept. of Pathology, New York, NY 10016, United States.
• Additional authors for this research include Sarra Belakhoua, Varshini Vasudevaraja, Chanel Schroff, Kristyn Galbraith, Misha Movahed-Ezazi, Jonathan Serrano, Yiying Yang, Daniel Orringer, John G. Golfinos, Chandra Sen, Donato Pacione and Nidhi Agrawal.